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Abstract
The life-threatening infections caused by Leptospira serovars demand the need for designing anti-leptospirosis 
drugs. The present study encompasses exploring inhibitors against phosphoheptose isomerase (GmhA) of Lepto-
spira, which is vital for lipopolysaccharide (LPS) biosynthesis and is identified as a common drug target through 
the subtractive genomic approach. GmhA model was built in Modeller 9v7. Structural refinement and energy 
minimization of the predicted model was carried out using Maestro 9.0. The refined model reliability was assessed 
through Procheck, ProSA, ProQ and Profile 3D. The substrate-based virtual high-throughput screening (VHTS) in 
Ligand.Info Meta-Database tool generated an in-house library of 354 substrate structural analogs. Furthermore, 
structure-based VHTS from the in-house library with different conformations of each ligand provided 14 novel 
competitive inhibitors. The model together with insight gained from the VHTS would be a promising starting 
point for developing anti-leptospirosis competitive inhibitors targeting LPS biosynthesis pathway. 
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Introduction
Leptospirosis is a widespread zoonotic disease caused 
by the spirochete Leptospira that is pathogenic for 
human (1). More than 500,000 cases of severe lepto-
spirosis occur annually in the world (2). It is pre-
dominantly an occupational disease that affects per-
sons in frequent contact with infected rodents, pet 
animals or polluted water, and the spirochete pene-
trates the human body through skin or mucous mem-
branes (3-6). The symptoms of leptospirosis are ex-
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tremely broad from meningitis, pneumonitis, hepatitis, 
nephritis, pancreatitis, erythema nodosum and death 
(7). Progression to multi-organ system complications 
occurs in 5% to 15% of cases, with mortality rates of 
5% to 40% (8).  
Leptospira has over 200 pathogenic serovars di-
vided into 25 serogroups and many different strains 
with small antigenic differences in some serovars (7). 
The complete genomic sequences of four pathogenic 
Leptospira (L. interrogans serovar Lai str. 56601, L.
interrogans serovar Copenhageni str. Fiocruz L1-130, 
L. borgpetersenii serovar Hardjo-bovis JB197 and L.
borgpetersenii serovar Hardjo-bovis L550) were se-
quenced and released (9-11). Extensive variation in 
the number and the distribution of insertion sequences, 
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genomic islands and other genomic contents was ob-
served during genomic comparison of serovars Lai 
and Copenhageni (2), which eventually determines 
the unique phenotypes of each strain. The whole ge-
nome sequencing of pathogenic and non-pathogenic 
strains extended the vaccine development process 
significantly along with development of a vaccine 
ontology database (7, 12). However, the heterogene-
ous group of pathogenic and saprophytic leptospires 
always remained a challenge for immunologists to 
develop an effective and safe leptospirosis vaccine (7). 
Although early treatment for leptospirosis is impor-
tant for ensuring a favorable clinical outcome, it is 
often difficult to achieve, as symptoms during the 
early stages of infection resemble those of several 
other systematic diseases (7). Specific antibiotic 
treatment using doxycycline or penicillin has shown 
mixed results for mild or sub-clinical infections, nev-
ertheless treatment of severe leptospirosis (organism 
localized in tissues) is still unclear (4, 13). Identifica-
tion of potential drug targets for L. interrogans 
through the substractive genomic approach (13, 14) 
has laid an attempt for exploring drug targets for 
screening novel lead compounds to improve leptospi-
rosis treatments. 
Lipopolysaccharide (LPS) is an essential compo-
nent of the outer membrane in Gram-negative bacteria 
(15, 16). LPS not only functions as a protective bar-
rier preventing cell entry of hydrophobic molecules, 
but also helps maintain the structural integrity of the 
outer membrane. LPS of Leptospira contributes to the 
pathology associated with diseases and comprises the 
major surface component of leptospires (16, 17). 
Studies with monoclonal antibodies have shown that 
LPS is a target for agglutinating and osponizing anti-
bodies (18). Thus, LPS plays a key role in immunity 
to infection. Indeed, anti-LPS monoclonal antibodies 
provide passive protection against infection, and puri-
fied LPS can stimulate active immunity (19, 20). LPS 
being an agglutinating antigen is also important for 
serological classification of leptospires. Thus, LPS is 
vital for leptospiral survival, virulence and antibiotic 
sensitivity, and enzymes controlling this pathway are 
of significant interest as molecular targets for new 
antimicrobial intervention. The structure of LPS is 
largely unknown. However, chemical analysis re-
vealed that LPS of L. interrogans serovar Co-
phanegeni and L. borgepetersenii serovars Hardajo is 
consistent with composition similar to that of the 
typical Gram-negative bacteria (21, 22). LPS com-
prises of Lipid A, a core oligosaccharide, and in some 
bacteria, an O-specific polysaccharide chain. The core 
oligosaccharide has an inner core region consisting of 
3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) and one 
or more heptose units, and an outer core consisting of 
an additional core residue (22-25). Lipid A and Kdo 
are highly conserved in Gram-negative bacteria and 
essential for cell viability. The biosynthesis of these 
molecules is therefore target for traditional antibiotic 
discovery efforts (26). Most Gram-negative bacteria 
also contain one or more L-glycero-D-manno-heptose 
molecules attached to Kdo. Mutants in heptose me-
tabolism are avirulent and highly susceptible to anti-
biotics, thus inhibitors of heptose biosynthesis could 
be used as anti-virulence drugs (27).  
Phosphoheptose isomerase (GmhA) was identified 
as putative common drug target for L. interrogans 
serovars (13, 14). Heptoses targeted to inner core LPS 
are synthesized within the cytosol as ADP-activated 
L-glycero-ȕ-D-manno-heptose molecule (28-30). The 
biosynthesis starts with GmhA catalyzing D-sedoheptulose- 
7-phosphate (S7P) to D-glycero-D-manno-heptose 
7-phosphate. The isomerization reaction is the first 
committed step of LPS biosynthesis (16). Thus, un-
derstanding the structure and function of GmhA 
would be useful to discover novel inhibitors.  
In the present study, a 3D structural model of 
GmhA was predicted using homology modeling tech-
nique. Structural refinement and energy minimization 
of built 3D model was done using Maestro 9.0. The 
structural quality of the predicted model was verified 
using Procheck, ProSA, ProQ and discrete optimized 
protein energy (DOPE) profile. Validity of the model 
was assessed by docking natural substrate S7P. The 
purpose of our study was to use virtual high-  
throughput screening (VHTS) to find novel inhibitors 
of the modeled GmhA followed by scoring and rank-
ing of the compounds to identify potential leads. The 
novel competitive inhibitors proposed here would be 
highly useful for developing antimicrobial drug 
against leptospirosis. 
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Results and Discussion 
GmhA as drug target 
Diverse groups of pathogenic and saprophytic lepto-
spires, and differences in the number and the distribu-
tion of insertion sequences, genomic islands and other 
genomic contents among Leptospira serovars (2, 7) 
make it difficult to develop effective drug or vaccine 
against leptospirosis. A common drug target for all 
pathogenic leptospires would be ideal to discover 
novel leptospirosis drug candidate. GmhA was identi-
fied as a common drug target among four pathogenic 
leptospires (genome sequencing completed till date) 
through the subtractive genomic approach. GmhA is a 
homodimer consisting of chains A, D and B, C. Each 
chain has 195 amino acid residues. Raw sequence of 
GmhA, available at the UniProt (ID: Q72RC1), was 
retrieved (Table 1). The selected drug target protein 
had 100% sequence identity with both L. interrogans 
serovars (Lai and Copenhageni) and 92% sequence 
identity with two L. borgpetersenii serovars 
(Hardjo-bovis JB197 and Hardjo-bovis L550). The 
GmhA active site residues were 100% conserved 
among four pathogenic Leptospira serovars. Current 
research approach was intended towards proposing 
GmhA as the molecular target for structure-based 
drug discovery against leptospirosis. 
The enzyme binds with S7P to give rise to 
D-glycero-D-manno-heptose 7-phosphate in an isom-
erization reaction, which is the starting point of LPS 
biosynthesis pathway (16). Pathway analysis at the 
KEGG revealed that there was no alternative way for 
D-glycero-D-manno-heptose 7-phosphate formation 
in the absence of GmhA. Comparative analysis of 
human and Leptospira metabolic pathways revealed 
that LPS biosynthesis pathway was unique to Lepto-
spira. The study coincides with the finding in Myco-
bacterium tuberculosis (31). Hence, designing novel 
competitive inhibitor to block GmhA active site 
would stop LPS biosynthesis, disintegrate the LPS 
protective barrier, and dissolve the structural integrity 
of the outer membrane and virulence factor of the 
pathogen.  
Homology modeling 
Homology modeling is an efficient method for 3D 
structure prediction and quick experimental design for 
docking studies. In general, 30% sequence identity is 
required for generating useful 3D structure models 
(32-34). Crystal structure of Escherichia coli GmhA 
(PDB ID: 2I22) having 42% identity with the drug 
target was selected as template. The template protein 
is a homodimer and the active site residues are present 
within B and C chains. The active site residues were 
conserved in both target and template sequences 
(Figure 1). Twenty quaternary structures of GmhA 
were generated in Modeller9v7 (32, 33). The substrate 
S7P was incorporated into the model from the tem-
plate to increase overall model accuracy (32, 33). All 
models have the same GA341 score of 1.00, which 
represents that the GmhA protein fold regions were 
predicted correctly in all 20 models. So, the fourth 
model having the lowest DOPE score was selected 
and subjected to model validation (32, 33). 
Model validation 
Reliability of the model was checked using diverse 
techniques. The DOPE profile plots (Figure S1) of 
leptospires (target) and E. coli (template) GmhA 
crystal structures were found quite similar (32, 33). 
The active site residues overlapping in the profile plot 
showed higher accuracy level of the predicted model 
(32). The stereochemistry of the model (Procheck 
analysis) revealed that 91.2% residues were posi-
tioned in most favorable region of the Ramachandran 
plot and was found to compare favorably with data of 
crystal structure: 2I22 90.1% (Figure S2A and B). 
Evaluation of GmhA 3D model with ProSA-web re-
vealed a compatible Z score value (A chain = í5.35, 
D chain = í5.67; B chain = í5.27, C chain = í5.42) 
within the range of native conformations of crystal 
structures (35). The ProSA-web analysis showed that 
Table 1 Raw sequence of GmhA of Leptospira accessed from UniProt (Q72RC1)
MDIKEIALGQIRDSIATKQKCIDSILEDIIKAGEIVSKILQAGNTIFLCGNGGSSCDASHIAAELVVRYKSGNERKALPALSLS
ADSAVLTACSNDYGYEEIFSRQIEAFGRKGDLLIGLSTSGNSKNVLLALEKAKTRGVKTISLLGGDGGKMKNLSDLDVIVP
SNVTARIQESHILIGHIICSIVEYNLFKME 
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Figure 1 Multiple sequence alignment of GmhA (four chains) with template 2I22. Dashes represent insertions and deletions. The 
conserved residues involved in active site are shown in boxes. 
 
the overall residue energies of the GmhA 3D model 
were largely negative (importantly all active site and 
its surrounding residues were also largely negative) 
expect for few peaks. The residue energies including 
pair energy, combined energy and surface energy 
were all negative and had similar surface energy 
tendency with template. The Z score and residue 
energies of GmhA dimer B, C are illustrated in Fig-
ure 2. The prediction efficiency of protein quality 
predictor (ProQ) tool increases by 15% when the 3D 
model was evaluated along with its secondary struc-
ture. A ProQ LG score >4.0 is necessary for sug-
gesting that a model is of extremely good quality 
(36). While submitted to ProQ tool, the secondary 
structure (Figure S3) and the 3D model (Figure 3A) 
of GmhA showed LG score of 5.285, implying the 
high accuracy level of the predicted 3D model. Ter-
tiary structure superimposition of template and target 
using superpose command in Modeller showed CĮ 
RMSD of 0.47 Å and an overall RMSD of 0.76 Å. 
The low overall RMSD reflects the high structural 
conservation. Structural alignment between the tar-
get and the template showed that the alpha helices 
and beta sheets matched accurately with each other 
(Table 2), representing that the GmhA 3D model is 
highly reliable. Through this assessment and analysis 
process, we concluded that the GmhA model gener-
ated in the present study is reliable to characterize 
protein-substrate and protein-ligand interactions and 
to investigate the relation between the structure and 
function. The validated GmhA model was submitted 
to protein model database (PMDB), which has ac-
cepted the model with less than 3% stereochemical 
check failures. PMDB ID for the developed GmhA 
model in complex with S7P was PM0075993. 
Active site region
Active site of the model was analyzed to assess pres-
ence of catalytic and conserved substrate binding 
residues. Presence of active site in the interaction site 
of B and C chains was confirmed through structure 
visualization using PyMol (Figure 3A and B). Active 
site residues (Asn51, Gly53, Ser54, Thr122, Thr169, 
Ala170, Gln173 of B chain, and His60, Glu64, His181 
of C chain) were identified by selecting residues 
Genomics Proteomics Bioinformatics 2010 Dec; 8(4): 246-255 249
Umamaheswari et al. / Leptospira GmhA Inhibitor Identification
Virtual high-throughput screeningwithin 4 Å of the substrate. The substrate forms six 
hydrogen bonds with the active site residues: two with 
Thr169 and one each with His60, Glu64, His181 and 
Thr122, respectively. The substrate interaction pattern 
in the GmhA catalytic site contemplates well with the 
findings in the crystal structure of GmhA of E. coli 
(16). Glu65 and His180 were the most critical resi-
dues for GmhA activity in E. coli (27-30). The present 
study revealed that Glu64, His181, Thr169, Thr122 
and His60 were identified to be critical for GmhA 
activity in L. interrogans.  
One of the most widely used methods for VHTS is 
docking of small molecules into active site of protein 
target and the subsequent scoring. A wide range of 
different docking programs are available, most of 
which use semi-rigid docking, where the ligands are 
treated as flexible and the receptors as rigid. The 
Glide 5.5 software was used for protein-ligand dock-
ing. It offers full spectrum of speed and accuracy from 
VHTS of millions of compounds to extremely accu-
rate binding mode predictions, providing consistently 
high enrichment at every level. 
 
Figure 2 ProSA-web Z-scores of modeled protein in PDB determined by X-ray crystallography (light blue) and NMR spectroscopy 
(dark blue) with respect to their length. Z score is represented in black dot. The energy plots were presented with window size 10 
(light green) and window size 40 (dark green). A. The Z-score plot of GmhA chain B. B. Energy plot of GmhA chain B. C. The 
Z-score plot of GmhA chain C. D. Energy plot of GmhA chain C. 
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Figure 3 A. GmhA 3D model in complex with substrate S7P (A chain: red; B chain: yellow; C chain: green; D chain: dark blue; 
Substrate: pink). B. Active site residues of GmhA 3D model (B chain: yellow; C chain: green; Substrate: red). 
Table 2 Structural alignment data of GmhA 3D model and template 2I22 listing exact matches of alpha helices and beta sheets
GmhA 3D model 2I22 
Alpha helice residue range Beta sheet residue range Exactly matching alpha helices Exactly matching beta sheets 
11-25 46-50 6-20 41-45 
30-41 80-82 25-36 73-75 
54-69 116-120 49-64 95-99 
102-110 142-148 81-89 121-127 
127-139 160-164 106-118 139-143 
169-191  148-170  
 
Virtual screening from in-house GmhA substrate 
analog library was performed using Glide 5.5. A total 
of 12,424 protonation and tautomeric states were 
generated from 354 substrate analogs using LigPrep, 
from which 1,919 conformers were retained during 
post LigPrep. A total of 655 conformers were passed 
in Lipinski filter and reactive filter from 1,919 con-
formers. The dataset was further condensed to 65 
based on best scoring ligands through VHTS, out of 
which 14 ligands were identified as lead candidates 
through careful inspection of the docking poses and 
possible interactions with the active site for all of the 
active compounds. All lead molecules satisfies phar-
macological properties of 95% drugs.  
The 14 novel lead molecules were ranked based on 
the Glide score and tabulated (Table S1). The best 
ranked lead demonstrated a Glide score of í8.39 
Kcal/mol. The active site of the GmhA is present in B 
and C dimer. Thus, careful observation of the docking 
poses of 14 novel GmhA competitive inhibitors were 
made to find the binding modes. Two sets of binding 
modes were observed in the docking poses. Lead 5, 
lead 11 and lead 12 were directly interacting with 
Glu64 of C chain by forming hydrogen bond and at 
the same time interacting with the active site residues 
of B chain by forming hydrogen bond network. The 
remaining inhibitors (except lead 5, lead 11 and lead 
12) were mainly confined to B-chain active site resi-
dues. Lead 5 showed a similar binding mode as that of 
substrate S7P. Lead 5 formed three hydrogen bonds 
with Gly53, Glu64 and Thr169 (Figure 4). The two 
hydroxyl groups of lead 5 acted as donors for forma-
tion of hydrogen bonds with carboxylic group of 
Glu64 and hydroxyl group of Thr169, respectively. 
Backbone nitrogen atom of Gly53 acted as hydrogen 
bond donor to form hydrogen bond with NH2 group 
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Figure 4 Interaction of novel lead (lead 5) in the GmhA active site forming three hydrogen bonds with Glu64, Thr169 and Gly53. 
A. GmhA whole protein and lead 5 (competitive inhibitor). B. Binding surface and inhibitor surface. 
 
of lead 5. The residues Asn51, Gly52, Gly53, Ser54, 
His60, Glu64, Thr122, Thr169, Ala170, Gln173 and 
His181 were involved in van der Waal interactions in 
the scaling 1.0. Lead 5 demonstrated a Glide score of 
í7.60 Kcal/mol, which is well above the S7P and 
GmhA Glide score of í3.19 Kcal/mol. Thus, based on 
the binding mode, lead 5 may be considered as the 
best lead molecule among the 14 novel inhibitors 
proposed in the present study for GmhA competitive 
inhibition. 
Validation of docking results
Natural substrate S7P was docked flexibly into GmhA 
active site for validation of identified lead candidates 
as competitive inhibitor. S7P was docked with a Glide 
score of í3.41 Kcal/mol. The lower Glide score 
(í8.39 to í7.41 Kcal/mol) of identified lead candi-
dates compared to S7P docking complexes revealed 
that the novel leads would bind more competitively 
into GmhA active site. Glu64, one of the critical resi-
dues for isomerase activity of GmhA, was mutated 
with Asp64. Docking of 14 novel lead molecules and 
S7P into mutated GmhA model was found to accom-
modate them in the catalytic cleft with slightly dis-
torted form and lower binding affinity except lead 11 
(Table S1). On the other hand, minute changes in the 
catalytic cleft can be influenced by slight changes in 
the backbone residues that do not reside in the inter-
face. Also, it is highly plausible that hydrogen bond-
ing of the active site residues holds the key for de-
signing potent selective inhibitors. The result revealed 
specificity of substrate S7P and identified novel lead 
molecules towards Glu64 in the active site of GmhA. 
Thus, the identified 14 lead molecules could be des-
ignated as novel inhibitors. GmhA being unique and 
the active site being 100% conserved to leptospiral 
serovars, designing competitive inhibitors based on 
these 14 lead molecules (Table S1) would be highly 
effective against leptospirosis. 
Conclusion
Extensive variation of genomic content in Leptospira 
strains always remains a challenge to find common 
inhibitor against leptospirosis. GmhA was identified 
for its uniqueness in the synthesis of L-glycero-D- 
manno-heptose as a common drug target to patho-
genic Leptospira strains through the subtractive ge-
nomic approach. Since GmhA controls the first com-
mitted step of LPS biosynthesis, it is of significant 
interest for novel inhibitor design. The assessment of 
GmhA modeled structure from L. interrogans re-
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vealed that it was of good quality with conserved ac-
tive site as that of the crystal structure of GmhA in 
other Gram-negative bacteria. Our approach employ-
ing Glide for virtual screening along with QikProp 
ADME evaluation provided 14 novel inhibitors for 
GmhA of Leptospira. These 14 inhibitors identified 
through VHTS using GmhA homology model for 
Leptospira would be of interest as common inhibitors 
against leptospiral serovars. Thus, it is hoped that the 
lead molecules identified in the present study hold 
promise for anti-leptospiral activities if synthesized 
and tested in animal models. 
Materials and Methods 
Hardware and software
The study was carried out on SGI Fuel Workstation 
with 3.0 GHz processor, 4 GB RAM, 300 GB hard 
drive and an Nvidia FX 1700 graphics card running in 
Linux operating system. Bioinformatics softwares, 
such as Modeller 9v7, Schrodinger software suite 
2009 and online resources, were employed to propose 
the outcomes of the study. 
GmhA of Leptospira as drug target 
GmhA was selected from the list of 88 common drug 
targets of L. interrogans serovars Lai and Copenha-
geni, identified through the substractive genomic ap-
proach (13). The GmhA protein sequence was re-
trieved from UniProt (http://www.uniprot.org/). The 
involvement of GmhA in leptospiral metabolic path-
way was analyzed at the Kyoto Encyclopaedia of 
Genes and Genome (KEGG) (37). The protein secon-
dary structure was predicted using PSI-PRED (38). 
Homology modeling of drug target
Homology modeling technique was implemented to 
predict 3D structure of GhmA. BLASTP (39) analysis 
of the GmhA protein was performed to obtain ho-
mologous entries from the protein data bank (PDB) 
(40). Co-crystallized structure of GmhA of E. coli 
with S7P (PDB ID: 2I22) was chosen as template. The 
BLASTP alignment was further refined using se-
quence alignment with default parameters in ClustalX 
(41). Python script was prepared to predict GmhA 
homodimer (A, D and B, C chain) 3D model incorpo-
rating S7P rigidly into the active site using Modeller 
9v7 (32, 33). A set of 20 models were generated and 
the structure with the lowest DOPE score was se-
lected for further analysis. To gain better relaxation 
and more correct arrangement of the atoms, refine-
ment was done on the built GmhA model using Maes-
tro 9.0 by applying OPLS-AA 2001 force field. The 
energy minimized GmhA model was assessed by 
Procheck (42), ProSA (35), ProQ (36), DOPE Profile, 
GA341 score and structure superimposition using 
SuperPose command (32, 33). DALI pairwise struc-
ture alignment tool (43) was used to align secondary 
structural elements of target 3D model with template 
crystal structure. The predicted GmhA 3D model was 
submitted to PMDB (44), which collects 3D models 
obtained by structure prediction methods. 
Ligand-based VHTS 
The substrate (S7P) atomic coordinates were 
downloaded from the PDB (16, 40). The substrate 
structure was imported to Ligand.Info Meta-database 
tool and 50 most structurally similar compounds were 
searched from each of eight sub-databases (45, 46).  
Consequently, an in-house library of 354 substrate 
analogs was generated.  
Docking and scoring 
Docking and scoring calculations were performed 
using Maestro 9.0. The substrate analogs were pre-
pared using LigPrep with Epik (47) to expand proto-
nation and tautomeric states at 7.0±2.0 pH units. 
High-energy ionization / tautomer states / ligands not 
following Lipinski rule of five / ligands with reactive 
functional group were removed from the generated 
conformations. A grid box of size 20×20×20 Å was 
generated on the receptor (modeled GmhA) by pick-
ing the active site residues using Glide 5.5 (48). Glide 
VHTS and standard precision method parameters 
were checked and set to save 10% of the good scoring 
ligands (48). The good scoring hits obtained from 
VHTS were validated based on S7P and GmhA Glide 
docking energy. Glu64, which was reported as a criti-
cal residue for GmhA substrate binding, was mutated 
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with Asp64 and the identified inhibitors and S7P were 
redocked into the active site to see the change in sub-
strate and inhibitor binding affinity. 
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